Trial Profile
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2019
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 16 Aug 2019 Status changed from recruiting to completed.
- 10 May 2017 Status changed from not yet recruiting to recruiting.
- 02 Dec 2016 New trial record